Jim Simons Novavax Inc Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Novavax Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 2,064,783 shares of NVAX stock, worth $18 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

2,064,783

Previous 1,110,183 85.99%

Holding current value

$18 Million

Previous $14.1 Million 85.56%

% of portfolio

0.04%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$10.71 - $17.11 $10.2 Million - $16.3 Million	954,600 Added 85.99%	2,064,783 $26.1 Million
Q2 2024 Aug 09, 2024	BUY	$3.89 - $20.97 $4.32 Million - $23.3 Million	1,110,183 New	1,110,183 $14.1 Million
Q2 2023 Aug 11, 2023	SELL	$6.67 - $9.52 $20.7 Million - $29.5 Million	-3,101,500 Reduced 87.6%	438,883 $3.26 Million
Q1 2023 May 12, 2023	BUY	$5.76 - $12.48 $4.14 Million - $8.97 Million	718,700 Added 25.47%	3,540,383 $24.5 Million
Q4 2022 Feb 13, 2023	BUY	$8.86 - $25.04 $17.2 Million - $48.6 Million	1,941,100 Added 220.43%	2,821,683 $29 Million
Q3 2022 Nov 14, 2022	BUY	$18.2 - $76.12 $16 Million - $67 Million	880,583 New	880,583 $16 Million
Q2 2021 Aug 13, 2021	SELL	$121.0 - $257.67 $81.4 Million - $173 Million	-672,683 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$112.98 - $319.93 $76 Million - $215 Million	672,683 New	672,683 $122 Million
Q4 2020 Feb 10, 2021	SELL	$78.74 - $139.5 $16.4 Million - $29.1 Million	-208,583 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$79.44 - $178.51 $16.6 Million - $37.2 Million	208,583 New	208,583 $22.6 Million

Others Institutions Holding NVAX

# of Institutions

290

Shares Held

93.4M

Call Options Held

6.95M

Put Options Held

9.4M

View Full List

About NOVAVAX INC

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $680M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

More about NVAX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account